Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL954461 | 1.00 | ADRA2C (0.38) | ADRA2CADRA1AADRA1BTRPV1 | |
| SCHEMBL1987964 | 1.00 | ADRA2C (0.38) | ADRA2CADRA1AADRA1BTRPV1 | |
| Hydrochloric Acid SCHEMBL18784069 | 0.98 | ADRA2C (0.37) | ADRA2CADRA1AADRA1BTRPV1 | |
| Hydrochloric Acid SCHEMBL953690 | 0.98 | ADRA2C (0.37) | ADRA2CADRA1AADRA1BTRPV1 | |
| SCHEMBL2345703 | 0.90 | ADRA2C (0.35) | ADRA2CADRA1AADRA1B | |
| SCHEMBL16472958 | 0.85 | L3MBTL1 (0.38) | ADRA2CADRA1AADRA1BTRPV1 | |
| SCHEMBL2957662 | 0.85 | ADRA2C (0.35) | ADRA2CADRA1AADRA1BTRPV1 | |
| SCHEMBL2953335 | 0.85 | ADRA2C (0.35) | ADRA2CADRA1AADRA1BTRPV1 | |
| SCHEMBL953544 | 0.83 | ADRA2C (0.39) | ADRA2CADRA1AADRA1BTRPV1 | |
| SCHEMBL957268 | 0.83 | ADRA2C (0.39) | ADRA2CADRA1AADRA1BTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109608368-B | Synthesis and resolution method of N- [4- (1-aminoethyl) -2, 6-difluorophenyl ] methanesulfonamide | 常州市阳光药业有限公司 | 2021-03-09 | — | — | CN | claimed |
| US-10858315-B2 | Method for preparing (R)-N-[4-(1-amino-ethyl)-2,6-difluoro-phenyl]-methanesulfonamide | AMOREPACIFIC CORPORATION (KR) | 2020-12-08 | — | — | US | claimed |
| US-20200031766-A1 | METHOD FOR PREPARING (R)-N-[4-(1-AMINO-ETHYL)-2,6-DIFLUORO-PHENYL]-METHANESULFONAMIDE | AMOREPACIFIC CORPORATION (KR) | 2020-01-30 | — | — | US | claimed |
| US-20170342027-A1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | AMOREPACIFIC CORPORATION (KR) | 2017-11-30 | — | — | US | claimed |
| EP-2054411-B1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORP (KR) | 2014-08-20 | — | — | EP | claimed |
| EP-2307394-B1 | SULPHONAMIDES AS VANILLOID RECEPTOR ANTAGONIST | AMOREPACIFIC CORP (KR) | 2012-09-26 | — | — | EP | claimed |
| JP-2011526625-A | — | — | 2011-10-13 | — | — | JP | claimed |
| US-7858621-B2 | Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same | AMOREPACIFIC CORPORATION (KR) | 2010-12-28 | — | — | US | claimed |
| WO-2010002209-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2010-01-07 | — | — | WO | claimed |
| US-20080312234-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2008-12-18 | — | — | US | claimed |
| CN-109608368-B | Synthesis and resolution method of N- [4- (1-aminoethyl) -2, 6-difluorophenyl ] methanesulfonamide | 常州市阳光药业有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-109608368-B | Synthesis and resolution method of N- [4- (1-aminoethyl) -2, 6-difluorophenyl ] methanesulfonamide | 常州市阳光药业有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-109608368-B | Synthesis and resolution method of N- [4- (1-aminoethyl) -2, 6-difluorophenyl ] methanesulfonamide | 常州市阳光药业有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-10858315-B2 | Method for preparing (R)-N-[4-(1-amino-ethyl)-2,6-difluoro-phenyl]-methanesulfonamide | AMOREPACIFIC CORPORATION (KR) | 2020-12-08 | — | — | US | disclosed |
| US-10858315-B2 | Method for preparing (R)-N-[4-(1-amino-ethyl)-2,6-difluoro-phenyl]-methanesulfonamide | AMOREPACIFIC CORPORATION (KR) | 2020-12-08 | — | — | US | disclosed |
| WO-2010002209-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009096701-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2009-08-06 | — | — | WO | disclosed |
| EP-2054411-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2009-05-06 | — | — | EP | disclosed |
| US-20080312234-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2008-12-18 | — | — | US | disclosed |
| WO-2008013414-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312234-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | ADRA2C 448/4885ADRA1A 370/4885ADRA1B 495/4885 |
| US-20170342027-A1 | CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES | DHCR24, SRR, ACMSD | ADRA2C 1709/4885ADRA1A 1488/4885ADRA1B 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.